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Abstract
Objectives: Men diagnosed with low‐risk prostate cancer are typically eligible for 
active surveillance of their cancer, involving monitoring for cancer progression and 
making judgements about the risks of prostate cancer against those of active inter‐
vention. Our study examined how risk for prostate cancer is perceived and expe‐
rienced by patients undergoing active surveillance with their clinicians, how risk is 
communicated in clinical consultations, and the implications for treatment and care.
Method: Participants were nine patients and three clinicians from a university hos‐
pital urology clinic. A staged, qualitative, multi‐method data collection approach 
was undertaken, comprising: observations of consultations; patient and clinician in‐
terviews; and patient surveys. The three data sets were analysed separately using 
thematic analysis and then integrated to give a comprehensive view of patient and 
clinician views.
Results: Thirty data points (eight patient surveys; 10 observations of consultations 
between patients and clinicians; 10 patient interviews; and two clinician interviews) 
combined to create a detailed picture of how patients perceived and appraised risk, in 
three themes of “Making sense of risk”, “Talking about risk” and “Responding to risk”.
Conclusion: Effective risk communication needs to be finely tuned and timed to in‐
dividual patient's priorities and information requirements. A structured information 
exchange process that identifies patients’ priorities, and details key moments in risk 
assessment, so that complexities of risk are discussed in ways that are meaningful to 
patients, may benefit patient care. These findings could inform the development of 
patient‐centric risk assessment procedures and service delivery models in prostate 
cancer care more broadly.
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1  | BACKGROUND
Prostate cancer (PCa) is the most commonly diagnosed male cancer 
in North America, Europe,1 and Australia2 and it is the fourth lead‐
ing cause of death amongst Australian men, where this study was 
undertaken.3 Although localized PCas (ie those with low histologi‐
cal grade and volume) have a very low risk of metastasizing and are 
unlikely to be fatal,4 untreated, aggressive cancers can metastasize 
to bone, lymph nodes and other organs, resulting in substantial mor‐
bidity and death.5
Men with cancer who are assessed as low risk, through pros‐
tate‐specific antigen (PSA) testing, MRI and biopsy, that are localized 
to the prostate, are potentially eligible for active surveillance (AS).6 
Rather than undertaking active treatments to remove or treat the 
cancer (such as radiotherapy, prostatectomy and hormonal therapy), 
AS involves regular monitoring for cancer progression.7,8 AS offers 
patients the choice of avoiding potentially unnecessary active treat‐
ments, while enabling timely review and intervention should the 
cancer progress. Previously termed “watchful waiting”,9 which im‐
plies a reactive, or palliative, approach7,10 to changes detected in the 
prostate (“come back and see me if anything changes”), current AS 
protocols act as an agreement between clinicians and patients that 
proactive monitoring of prostate health will take place. Appointments 
for reviewing PCa are often planned in advance, with time frames 
ranging between 3‐ and 6‐monthly appointments. AS requires the 
active participation of the patient to ensure that risk is effectively 
monitored through repeated testing, such as PSA and MRI, and fol‐
low‐up urology appointments. The appointment schedule is deter‐
mined by patients’ individual requirements, such as their stage of life, 
family history, Gleason score (a grading system to identify the aggres‐
siveness of the tumour) and the likelihood of the tumour recurring.
The decision to take part in an AS protocol involves patients, 
in discussion with clinicians, weighing the risks of regularly moni‐
toring of PCa against those of active treatment, based on the cli‐
nician's judgement. The risks of active interventions can include 
serious side‐effects impacting a patient's bladder and bowel 
continence, erectile function, fertility and hormone balance,11 
which then require management from multiple health services. 
Nevertheless, AS protocols are not without risk of negative ef‐
fects. Patients may be asked to regularly undergo invasive and 
discomforting biopsies, ultrasounds, and expensive imaging pro‐
cedures, such as multi‐parametric MRI scans.12,13 Moreover, as it 
does not involve the eradication of the cancer, AS may be associ‐
ated with anxiety and uncertainty.14,15
Patients’ perceptions of risk and their certainty of the effective‐
ness of treatments for PCa are influenced by their understanding 
of clinical outcomes,15,16 in turn affected by a number of psycho‐
social factors, such as family support, clinician communication and 
attitude,16 and anxiety and distress.7 In this study, we sought to un‐
cover the experiences of men with low‐risk PCa responding to the 
risks associated with their cancer.. We aimed to identify risk from 
the perspective of men with localized PCa, who were considering or 
using an AS protocol to manage their risk of cancer metastasizing, 
and from the perspectives of their treating clinicians. We asked: (a) 
“How do patients perceive and experience risk for PCa; and how is 
risk communicated between clinicians and patients’?” and (b) “What 
are the implications of patients’ perceptions of risk on their treat‐
ment and care?”
In this study, we define risk as the probability of a particular clin‐
ical event occurring,17 such as the risk of PCa metastasizing. Risk is 
typically expressed to patients in terms of numbers,18 to describe 
probabilities, including percentages of patients who may experience 
side‐effects from curative treatments, or the likelihood of death at 
10 years for those on particular treatments. Even though risk is ex‐
pressed in terms that are clinical (impacting on a person's physical 
health) patients can also experience risk in ways that are non‐clin‐
ical (impacting on their quality of life) or in terms of psychosocial 
implications (impacting on their relationship and mental health).16 
Risk communication in this study builds on our previous work in un‐
derstanding how risk is discussed with patients, and expressed, in 
breast cancer.17,19
2  | METHOD
2.1 | Setting
The project was conducted in an Australian university hospital urol‐
ogy clinic, between November 2016 and December 2017. The clinic 
is part of a private practice outpatient service, attached to the uni‐
versity hospital, serving the needs of a diverse patient demographic 
and offering wide‐ranging clinical services. Ten Urologists see pa‐
tients in their clinic rooms, and while the senior clinician practises 
solely at the university hospital clinic, the remaining nine Urologists 
see patients at multiple clinic sites. General practitioners (GPs) 
refer patients directly to the Urologists as private practitioners, 
rather than to the urology clinic. As such, each Urologist's caseload 
is separate to that of the other Urologists. The Urologists attend a 
fortnightly multidisciplinary team meeting to discuss their patients 
collaboratively and to examine patients’ cases in detail. The patient 
flow pattern of the clinic is shown in Figure 1.
As the clinic is a private practice, in this study, the men who used 
the clinic services were generally from a middle socio‐economic 
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band, living in metropolitan areas and surrounding districts, with a 
small number travelling up to 2 hours to attend the clinic. The men 
were typically aged from mid‐40s to 70s and came from predomi‐
nantly white or south‐east Asian backgrounds. There was a mix of 
working and retired men, from occupations such as business and 
trade.
2.2 | Recruitment
The study was advertised using flyers placed in the Urology clinic 
waiting room area, to ensure that patients visiting the clinic were 
aware that the research was taking place. In addition, patients con‐
sidered suitable for the study (that is, those who were clinically ap‐
propriate candidates, who had PCa, were under or considering AS, 
and showed no psychological sign that involvement would raise anx‐
iety levels or lead to any undue harm) were identified by the two par‐
ticipating Urologists from their patient lists and recruited according 
to a time frame sampling approach.20 Time frame sampling indicates 
that where a small number of potential participants are involved in 
clinical consultation over lengthy periods of time, recruitment should 
encourage all those who consult within that period to be offered the 
opportunity to participate. People are not conveniently chosen (con‐
venience sampling) rather all patients are approached and all who 
agree to participate are included. Thus, the time frame is chosen in 
order to allocate the recruitment period. The approach captures the 
views and experiences of all consenting eligible participants who fit 
the appropriate study criteria within a specified window of opportu‐
nity, and who are considered suitable (physically, mentally and emo‐
tionally) for study inclusion by the clinicians overseeing their care. 
What is limited is the period of recruitment and not the opportuni‐
ties for patients to participate, while the sampling technique reduces 
clinician and researcher coercion and removes researchers from 
decisions about eligibility. In this study, research team members did 
not come into contact with patients at the recruitment stage, thus 
upholding patient anonymity and data confidentiality and while re‐
search team members were invited to attend the clinic on the days 
that patients attended, clinicians discussed the study further with 
patients before any researcher involvement. If patients were ame‐
nable to learning more about the study, one of two researchers (AH 
and KC), attending the clinic on the day of the patient's visit, made 
contact to introduce the study to them, offer more information and 
ask if they still wished to participate. If patients agreed, they signed 
a written consent form.
2.3 | Data collection
A multi‐method, staged approach was used to gather data,21 com‐
prising: patient surveys; observations of consultations between pa‐
tients and clinicians; and individual interviews with patients, and 
with clinicians. Data collection was planned to be consecutive with 
one stage following the next, so that surveys would precede ob‐
servations, and be followed by interviews. However, this was not 
always feasible, as some patients were referred to the study after 
their consultation appointment, while others were not available to 
participate in an interview on the same morning as their clinic ap‐
pointment. Thus, the researchers conducted each stage of the data 
collection procedure consecutively yet at the convenience of the 
participants.
The patient survey was purpose designed for the study, based on 
information gained through discussion with the Urology Clinic team. 
Survey questions covered demographic and health‐care questions 
(Appendix S1: Survey questions). Data collection was opportunistic, 
with surveys completed prior to observations or more commonly at 
the start of interviews. Moreover, discussion of the survey ques‐
tions frequently became part of the interview, as participants re‐
quested clarification on some of the questions and expanded on 
their responses.
Observations of consultations took place in each Urologist's con‐
sulting room. For most patients, the consultations were the first or 
second clinic appointment after their biopsy. Sessions were audio‐
recorded, and the researcher used a structured observation check‐
list (Appendix S2: Observation checklist) to note the interaction 
between clinician and patient. The checklist guided observations of 
non‐verbal aspects of communication between the patient and cli‐
nician, such as body language, and recorded the use of written and 
visual materials to support medical information.
Participant interviews followed the observation of the consulta‐
tion. Two interview guides were used—one for patients and one for 
clinicians (Appendix S3: Interview guide for patients; Appendix S4: 
Interview guide for clinicians). Interview questions were semi‐struc‐
tured; that is, the topic of the question was stated, followed by an 
open‐ended example question that acted as a prompt for further 
information. This format served to elicit in‐depth responses from 
participants and allowed the interviewer to ask for more detail if 
needed. It also avoided any duplication of information if participants 
had discussed the topic at length while completing the survey.
Patients and clinicians were interviewed in a location of their 
choice for up to 1 hour. Some chose to be interviewed in the clinic on 
the day of their consultation appointment, some to be interviewed 
during the following week from home (face‐to‐face, or by phone), 
while others chose settings close to the clinic (for example, the hos‐
pital café or researcher's office). One patient volunteered to partic‐
ipate over the 12‐month data collection period and to demonstrate 
an extended patient journey. This patient took part in one survey, 
three observations of consultations with one Urologist and three 
interviews.22
2.4 | Data analysis
The analysis process was systematic and iterative, with codes de‐
rived from the data and involving contributions from multiple data 
sources and several members of the team. The three forms of data, 
in line with a staged approach to data capture,23 were first analysed 
separately. Once complete, the data sets were integrated as one 
combined data set, to provide a more comprehensive view of patient 
and clinician perceptions and experiences.
     |  1031HOGDEN Et al.
2.4.1 | Survey data
Participant data from the demographic surveys were compiled, ana‐
lysed descriptively and summarized (Table 1).
2.4.2 | Observation data
Observations of consultations between patients and the two 
Urologists were undertaken. Eight of the consultations were audio‐
recorded and transcribed. Two patients requested that only field 
notes of their consultations were taken and that the consultations 
were not audio‐recorded. Observation data were read through by 
the researcher who had attended the appointment, to identify the 
relationship between observation notes and interview data and how 
observations added depth of understanding to interview data, in 
particular, around risk communication between clinician and patient. 
Observation findings were assessed thematically, and key themes 
were merged with themes derived from interviews to form a richer 
narrative of the consultation that was representative of the interac‐
tions between the Urologists and patients.
2.4.3 | Interview data
Data were analysed in a stepwise procedure to ensure rigour. First, 
two researchers independently read through a sample of four patient 
interview transcripts. Participant statements were coded for mean‐
ing in relation to the research question, and study aims and objectives 
taking account of approaches to transmitting information about risk, 
communication strategies, and strategies for reducing uncertainty. 
The researchers then met to discuss the codes that emerged and 
TA B L E  1   Survey data summary (8/9 respondents)
Topic Category Subcategory Result
Health characteristics Time since diagnosis Within last few weeks 1
Within last 3 mo 5
3‐6 mo 1
Not diagnosed 1
Services consulted other 
than clinic
 Radiology × 2
Health visits for PCa 1‐2 6
2‐5 2
Decision for AS or 
treatment
Decided 6 (4 AS; 1 radiation; 1 surgery)
Undecided 2
Awareness of risk 
classification
Yes 6
No 2
Information sources Doctor in clinic 8
Doctor in hospital 1
Nurse/other 1
Internet 5
Friends/family 3
Other GP; 2nd opinion
Top ranked priority Staying physically healthy and 
living a long life
7/8
Emotional/mental/social 
well‐being
1/8
Lowest ranked priority Limiting the impact of prostate 
cancer treatment on your life
5/8
Demographic characteristics Age range 40‐49 2
50‐64 2
65‐79 4
Sexual orientation Heterosexual 8/8
Relationship status Married 7
Single 1
Cultural background Anglo‐Australian 8/8
Education level Uni deg or higher 5
High school 2
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agreed on an initial thematic coding framework24 that could be ap‐
plied to code the remaining transcripts. Patient and clinician interview 
transcripts were then uploaded into NVivo 11 (QSR International) to 
manage the data efficiently and to assist with the understanding of 
theme development. Once all the transcripts were read as a complete 
data set, additional codes that were not captured in the initial sam‐
ple were identified. The coding framework was discussed by the two 
researchers and amended to complete the preliminary analysis. One 
researcher grouped the codes to form subthemes as they emerged 
from the data. For example, the code “clinician's risk representation” 
formed part of the subtheme “communicating risk to patients” and 
then rolled up into the overarching theme of “talking about risk”. The 
themes and subthemes were discussed within the wider research 
team (comprising health‐care professionals and academic research‐
ers) using tried and tested group work activities25 until consensus on 
key themes emerging from the thematic analysis was reached.
2.4.4 | Combined data
Members of the study team reviewed the analysis of each data set 
and discussed the meaning of the combined findings. Ongoing dis‐
cussions ensued until a final thematic framework emerged across all 
study stages. This was supported by the corroboration of observa‐
tion findings with interview findings, alongside the patients’ priori‐
ties for their health and well‐being, indicated in the surveys. These 
combined data sets were reanalysed for agreement or disagreement 
between data sources. Minor inconsistencies across data sets were 
discussed and addressed early in the process, leading to a more com‐
prehensive set of findings, for deeper understanding of the data and 
consideration of further research questions.26,27
3  | RESULTS
In total, 30 sources of data were collected and compiled: eight pa‐
tient surveys; 10 observations of consultations between patients 
and clinicians; 10 interviews with patients; and two interviews with 
clinicians (one Urologist and the specialist Prostate Cancer Nurse, 
Table 2).
Nine men (of 10 approached) consented to take part in the study. 
Eight men with a diagnosis of localized PCa, who were using or had 
considered an AS protocol, were enrolled. Of these, one man had 
previously undergone surgery to remove a high‐risk cancer and was 
now undertaking AS to monitor any recurrence. The ninth partici‐
pant did not have a PCa diagnosis, but had a strong family history of 
prostate cancer, who regularly undertook screening tests for onset 
of the disease that was akin to the AS protocol used in the clinic (see 
demographic data below for more detail on the patient cohort).
Clinician participants were two male Urologists (four Urologists 
were approached) and a male specialist Prostate Cancer Nurse. The 
three clinicians participated in different data collection activities. 
The two Urologists participated in observations of consultations, 
but no consultations with the specialist Prostate Cancer Nurse were 
observed. One Urologist and the specialist Prostate Cancer Nurse 
took part in interviews.
Of the nine patients considered suitable for an AS protocol, 
seven remained on AS, one opted for surgery and another for ra‐
diotherapy. Of the consultations, six were with one Urologist, and 
four were with the second Urologist. Patient consultations with the 
specialist Prostate Cancer Nurse were not observed.
Combined data generated a detailed picture of the way patients 
and clinicians perceived, discussed and responded to risk in this care 
setting. Disagreement between data findings was minor and there‐
fore is not presented; for example, the number of patients report‐
ing using friends as an information source differed slightly between 
survey and interview data. Three themes integrated the findings to 
represent patients’ appraisal of risk. These were “Making sense of 
risk”, “Talking about risk” and “Responding to risk”. Quotes illustrat‐
ing each theme are placed in tables and referenced to the related 
text. Participants are identified as either patient (P) or clinician (C).
3.1 | Making sense of risk
Patients reported making sense of the risks posed to them through 
understanding the meaning of their diagnosis, how it impacted on 
their personal priorities for their lives, and the information they ac‐
cessed to come to terms with their situation. Most patients were re‐
cently diagnosed, and their understanding of the risks posed to them 
Method Participants Totals
 Patients 9  
Clinicians 3 12
Surveys Patients 8 8
Interviews Patients 8 initial interviews (7 face‐to‐face; 1 by 
phone) 2 follow‐up interviews
10
Clinicians 
(C1, C2)
2 2
Consultations C2 6 10
C3 4  
Total data points   30
TA B L E  2   Data collection summary
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by PCa and participating in an AS protocol was new. Patients did not 
distinguish between clinical risk, non‐clinical risk and psychological 
risk, but in how PCa impacted on their length and quality of life, and 
whether the effect was of a physical, mental or emotional nature. 
Participants recalled their reactions to receiving the diagnosis of lo‐
calized PCa, with many reporting feelings of shock at the diagnosis. 
Some struggled to understand what it meant to their life, and how 
they should respond. Others drew on long‐held philosophies and 
personal beliefs to deal with their situation (Table 3, quote 1).
Risk was frequently perceived and expressed through the lens 
of patients’ personal priorities. Participants’ broader priorities, when 
selected from the survey categories, were frequently held in com‐
mon. For example, “Staying physically healthy and living a long life” 
was most frequently identified as a top priority, while the lowest 
ranked was “Limiting the impact of prostate cancer treatment on 
your life”. Nevertheless, patients’ perceptions of their own risks 
from PCa were more varied and nuanced when described at inter‐
view. Some defined their fears and risks in relation to their personal 
priorities, in concrete terms of how it might affect their quality of 
life, length of life and plans for their future (Table 3, quotes 2 and 
3). Others made sense of their risks through statistical information, 
applied to their goals for living. They found reassurance in publicly 
available information that helped them understand what it meant to 
be in a low‐risk category (Table 3, quote 4).
Participants identified a range of information sources they had 
used to understand their condition, their risks and what the future 
might hold, in addition to what was provided by their clinicians. 
These sources included a combination of Internet‐based information 
and family and friends’ experiences. Patients wanted Internet‐based 
information, but expressed difficulty in identifying information that 
related to them and their own risks. The Internet offered a broad 
range of information, but patients did not have the knowledge to 
read it selectively. Some reported feeling alarmed by information 
about advanced cancers and not knowing if this was their future 
(Table 3, quotes 5 and 6).
Several participants reported drawing on friends who had ex‐
perienced PCa as a source of support and information, but also 
as a warning. Learning from the experiences of friends influenced 
Number Quote
1 “I've got to attack it, but at no time during this was I anxious. To me, it was uncer‐
tain, but the uncertainty didn't turn into anxiety. I was just going to do it as an 
engineer, I mean, it could have got worse, but I just didn't know which way I was 
going to go”. P6
2 “Well, there's … shortened life in terms of, you're dead …shortened quality of life, 
excluding sex. That means, are you having a problem pissing, are you hindered 
[from doing] other things you can't do?... And thirdly, which, I've sort of held off 
separately, the enjoyment of sex.” P5
3 “I don't want the prostate ripped out because then that's goodbye to any chances 
of family”. P1
4 “I personally like to know what the real sort of risks are, and you look for some sort 
of comfort in the statistics in that they might say only 10% of people will progress 
from this stage, or whatever it might be, I guess that's what I was sort of looking 
for… at that point, you're just looking for some sort of reassurance, and some sort 
of higher level of—some way of minimising the worry”. P2
5 “With the websites, not being a medical professional, having that much knowledge 
around these things, I think it's dangerous to actually read them and infer any 
conclusions from it, because there can be such subtle differences that you just 
don't appreciate, don't know about, that can totally change it. For example, I was 
thinking at one stage, well, it says 20% of people might have cancerous cells by 
the time they're 50 … It's just a bit more information to understand, which is good 
and bad. You find good things, but you find bad things when you read that. That 
was my initial experience”. P2
6 “You've got to be a bit careful with the Internet ‘cause there's a lot of loonies out 
there that put stuff on”. P4
7 “At my age so many of my friends are now having it, so—and I've got another mate 
who didn't take any notice of it at all and he's now on major chemo”. P4
8 “I've known blokes in their 70’s who died very quickly, once it's sort of in you, it 
metastasises; but mine hasn't”. P7
9 “I got a lot of information from my father who had done quite an extensive 
research into it, but I've also done my own research on the internet … they were 
generally all saying the same thing. I went to medical websites but then also 
patient websites just to get their feedback and what they thought from the differ‐
ent options. And my father did quite a lot of research into that and was using his 
knowledge as well”. P8
TA B L E  3   Making sense of risk: 
Participant quotes
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patients’ appraisals of risks and complexities associated with the dis‐
ease, and with treatment options (Table 3, quotes 7 and 8).
One patient with a family history of PCa (father and grandfa‐
ther) drew on their collective experiences to motivate vigilance of 
his prostate health and to keep himself up to date with detection and 
treatment procedures (Table 3, quote 9). Patients also drew on infor‐
mation given to them by their clinicians during consultations. This is 
outlined in the following section, describing how risk was discussed 
in clinical consultation.
3.2 | Talking about risk
During consultations, clinicians used a patient‐centred approach 
to identify the most appropriate prostate cancer intervention for 
each patient. This approach was evident in the use of shared deci‐
sion‐making principles (such as discussion of evidence‐informed 
strengths and weaknesses of the treatment options, with refer‐
ence to the patient's values and preferences). The approach was 
put into practice to support patients to reach their decision from 
the way information was presented to the patient, and the inter‐
action between patient and clinician, both verbal and non‐verbal. 
Both Urologists adopted a similar approach to patient care, and 
the body language observed between patients and Urologists 
indicated that patients seemed relaxed and comfortable through‐
out their consultation and in discussing intimate details about their 
health and health‐care needs.
Interactions between patient and Urologist were generally led by 
the patient, either by presenting new information to the Urologist, 
checking that test results had been received, or requesting infor‐
mation about specific issues. Urologists responded by providing 
evidence‐based information from academic publications about the 
issue under discussion, for example, recommendations for diet or 
exercise. Information from the Urologists was delivered verbally, 
supported on occasion by use of anatomical models to clarify infor‐
mation about the prostate. Many patients brought notes as reminders 
of the concerns they wished to discuss, and these were raised with 
the Urologist as part of information sharing. Information about risk, 
in terms of survival rates, was presented verbally by the Urologist if 
the patient queried their lifetime risk or chance of survival.
During consultations, clinicians communicated risk information 
in several ways. Firstly, Urologists went through the assessment 
procedures used to diagnose and classify the cancer (PSA, MRI, bi‐
opsy), and which of those would be used to monitor change in the 
cancer (PSA, MRI). Secondly, clinicians described the tumour using 
Gleason scores, interpreted in lay terms for the patient. Thirdly, cli‐
nicians responded to patients’ concerns about their risks from PCa 
Number Quote
10 “They probably think they've been given a diagnosis of ‘you're going to die’, so 
giving reassurance first of all—firstly, [there's] no immediate danger, and secondly 
you need to actually get the right treatment to get a long and healthy life hope‐
fully”. C2
11 “Sometimes it's purely sitting down with the patient and just saying, ‘What are you 
worried about?’ You give your standard spiel, but then you go, ‘Well, what are you 
worried about? What's the big bugs for you?’ Especially it's a great thing if they've 
got the family [with them] because they can have different worries, ‘Well, what 
are you worrying about?’ If the kids are there, ‘What are you worried about?’” C1
12 “Even on a low‐grade cancer like yours, for example, if you leave them alone, 95% 
are going to be all right”. C2
13 “If you haven't got a prostate you can't be fertile; it's impossible. And usually as you 
get older you sort of discount that. But I've known a few people in their 50s, 60s, 
who still think about having children, so you need to take that into consideration”. 
C2
14 “Dr [Urologist] was very good, he was very supportive and there was another guy, 
I can't remember his name, he was a Nurse in that area. Nice guy, really nice guy. 
Between the two of them, they made sure that I was happy with what was going 
on, where I wanted to go, and they gave me all the scenarios of what I should do. 
I'm very grateful to both of them, they were both really good”. P4
15 “If the risks are, from what I can see, low, and it's not caused by my lifestyle, there‐
fore there's nothing to change. I'll just carry on as normal”. P1
16 “He's got a guy called [Nurse name] who is a very helpful guy. So, if I had a change 
I'd probably give [Nurse name] a call and say, hey I've got this change, should I 
come in and see the guy [Urologist]?” P3
17 “I'm in the hands of the medical expertise, and if they said, ‘Oh, we've got to slam 
you in hospital tomorrow and rip your prostate out, otherwise you're going to 
die,’ of course I'd do it. But given the fact that the advice I've received is Active 
Surveillance, it tells me that the risks are low, therefore I'm not doing terribly 
much about it”. P1
TA B L E  4   Talking about risk: Participant 
quotes
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by providing reassurance and addressing patients’ specific issues as 
they arose in the discussion (Table 4, quotes 10 and 11).
Clinicians communicated risk to patients using statistical prob‐
ability information, applied to each patient in terms of their age, 
health status and life goals (Table 4, quotes 12 and 13). Patients re‐
questing reassurance about lifestyle behaviours, such as their diet 
and exercise, were given advice based on emerging research infor‐
mation delivered verbally by the clinician.
Once the patient's concerns had been addressed, treatment op‐
tions appropriate to the patient's needs, including information about 
an AS protocol, were presented by the Urologist. The benefits and 
disadvantages of each potential treatment were made clear to the 
patient. A follow‐up plan was then negotiated, guided by the needs 
of each individual patient, and the recommendations for PCa care 
were offered. The consultation concluded with the Urologist's re‐
port to the GP being dictated while the patient was present. This 
ensured that patients were aware of the information being transmit‐
ted to their GP. While not observed, clinicians reported that health 
literature on PCa was made available during consultations with the 
specialist Prostate Cancer Nurse, alongside information about pros‐
tate cancer support services.
Patients expressed satisfaction in the care they received 
through the clinic, and trusted their clinicians’ judgement (Table 4, 
quotes 14 and 15). Patients and Urologists valued the availability 
of a specialist Prostate Cancer Nurse for booked appointments 
and phone consultations. The Nurse's role was viewed as inter‐
preting information and confirming advice after patients’ medical 
consultation. The Nurse was available to be contacted through‐
out the week, if patients had any concerns they had not raised 
during appointments. Perhaps related to this availability, patients 
reported feeling more confident to contact the Nurse than the 
Urologist (Table 4, quote 16).
However, as a new service, not all patients were aware that the 
Prostate Cancer Nurse was available to them. Those patients un‐
aware were informed of the service by the researcher. Once patients 
understood their risks, and how they could be proactively mon‐
itored through an AS protocol, they expressed confidence in how 
their prostate health was being managed by the clinic team (Table 4, 
quote 17).
3.3 | Responding to risk
As patients gained understanding of the risks they faced, they sought 
ways to take control over their health. This frequently took the form 
of self‐management approaches to minimize risks, reduce anxiety 
and uncertainty, and determine their way forward (Table 5, quotes 
18 and 19). A common approach was in seeking reassurance about 
their personal risk from PCa, to gain certainty about their treatment 
decisions. When patients had made their decision, many wanted the 
Urologist to confirm whether he thought they were making the right 
decision, by asking the Urologist what he would choose under the 
same circumstances (Table 5, quote 20). Moreover, the Urologists 
frequently framed their recommendations as what they themselves 
would do if they were the patient (Table 5, quote 21). One patient 
surmised the relief expressed by many, when they were able to fully 
appraise their risks, and move on to making management decisions 
for PCa (Table 5, quote 22).
4  | DISCUSSION
The findings from this study add to previous research in PCa care 
that has investigated patient decision making in PCa diagnosis and 
treatment,16 such as men's understanding of benefits and harms 
Number Quote
18 “I had to sort of pick myself up and say; ‘what am I trying to do here?’... So then I 
had two opinions … So I will now take management back … I can make sure it's 
monitored which I'm doing. I can yell out if there's any change in any of the activ‐
ity”. P3
19 “I can understand the different roads to be taken and the risks associated with 
each one. I plotted in my mind a map that works, and I think is logical for every‐
one's point of view”. P4
20 “P6: If it was your prostate, what would you do? 
C3: I’d have radiotherapy. I think it’s going to get a better shot at you, basically, 
with it. You’re also 73. The side effects of radiotherapy are less likely to affect 
you, versus a 53 or 63‐year‐old”.
21 “C2: If it were me, I’d probably watch the—I would watch the PSA, go for a MRI and 
then, you have a repeat biopsy as something on, you know, the persistent rise and 
the PSA and unless there’s something on the MRI that wasn’t there before … 
P5: Okay. So I’ll just do the PSA in three months and then, PSA and see you in six”.
22 “I was just so relieved to hear that there was nothing else found and that he was 
recommending the [Active Surveillance] that I thought, well, regardless of if it's 
a 20% chance of it progressing or a 60% chance of it progressing, what I need to 
do now is, is watch and wait and not worry about it, because I don't want to go 
through my life knowing that you're on a bit of a ticking time bomb”. P2
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associated with PSA testing28; and their decision‐making and treat‐
ment preferences.29,30 However, in this study, we have concentrated 
on risk, through qualitative interviews, observations and surveys. 
The evidence in our study suggested that effective risk communica‐
tion in PCa may benefit from fine tuning to individual patient's pri‐
orities and information needs. Based on evidence from observation 
of consultations and patient and clinician interviews, we propose a 
structured approach to information provision that emphasizes that 
informed decision making about interventions for PCa is a multilay‐
ered exchange of information.31 In this way, our findings build on 
previous recommendations for communicating risk in cancer, identi‐
fying helpful modes32,33 and structures31,34 for risk communication.
Clinicians in this study demonstrated that they balanced clinical 
judgement with evidence‐based information, to deliver a patient‐
centred approach when discussing risk in PCa, in response to the 
perceived needs of patients. Discussions of risk centred on under‐
standing patients’ priorities and preferences, to help them decide 
whether to choose or remain on AS or pursue active intervention.35 
Reflecting the preference‐sensitive nature of this decision, clini‐
cians gave assurances without explicitly directing patients towards 
an option and respected patients’ choices. Furthermore, access to 
a specialist Prostate Cancer Nurse within the clinic contributed to 
patients’ understanding of their cancer and the risks it posed to 
their survival,36,37 quality of life and psychological well‐being, as 
well as offering them reassurance that their PCa was being actively 
monitored using a protocol that reflected their priorities. Clinicians 
outlined individuals’ assessment results, and an estimation of their 
clinical risk, including rates of survival after 10 years, and addressed 
the pressing psychosocial concerns that patients raised, such as 
maintaining sexual activity.
Timing was central to patients receiving the information they re‐
quired to reduce their uncertainty and make treatment decisions.14 
For example, by their second consultation, after their biopsy, patients 
had received the information they needed about their tumour and 
the risks it posed to them. But it was the time preceding this, when 
patients did not understand their own risks and the implications of 
risk for their future health and well‐being, that created anxiety and 
uncertainty. Information gaps were mostly resolved after two clinic 
appointments, when there had been time to raise concerns with a 
Urologist and specialist Prostate Cancer Nurse. However, at the be‐
ginning of the patient journey, much was unknown—such as what 
risk meant, which risks personally related to an individual patient, 
and the full extent of the clinic service on offer. It may be that earlier 
risk information provided between first and second appointments 
following diagnosis would be an optimal solution to information pro‐
vision when patients most need it. This finding complements that of 
TA B L E  6   A process for enhancing patient risk communication
1. Information for clinicians
During their first clinic appointment, patients could be asked to complete a proforma (written or verbally) to gather information about their priori‐
ties, information needs and expectations of the clinic service. This information could be provided to the Urologist and specialist Prostate Cancer 
Nurse, to have patients concerns documented and indicate areas for discussion during the initial clinic appointment.
2. Information for patients
A. About the clinic service
Prior to the first clinic appointment, patients should be sent information about the urology clinic service. This could include details about the 
services provided by the clinic, including the specialist Prostate Cancer Nurse service; hours of operation and availability of the clinic staff; and 
contact numbers for the clinic. Additionally, some patients will have psychosocial needs that may be beyond the scope of the clinic to address. 
To ensure that patients’ psychosocial needs and related risks are fully assessed, details of a counselling service linked to the clinic should be 
included in the information given to patients.
B. About how risk is calculated and expressed in PCa clinical settings
As some patients are clearly unaware of, or do not fully understand, clinical risk classifications (low‐, medium‐ and high‐risk), and how the risk 
classification applies to them, patients would benefit from receiving written information about how risk is formally assessed and how Gleason 
scores are derived, including diagrams that explain what low‐, medium‐ and high‐risk classification means.
C. About PCa and treatment options
Following the initial appointment after biopsy, or whenever it is indicated that a patient is suitable to be considered for an AS protocol, pa‐
tients should be provided with information about active surveillance in PCa, and the benefits and disadvantages of AS and active treatments. 
Patient decision support tools exist for these reasons; however, there is a need for up‐to‐date tools that are user‐designed38 and specific to the 
Australian clinic context.35,39
D. About self‐management and risk minimization
Information should be created for all urology clinics to be handed to patients upon attendance that can support patient self‐management, that is, 
evidence‐informed health literature to address the information gaps identified by the participants in our study, including positive health behav‐
iours and potentially harmful behaviours to avoid.
3. Review
For the purpose of review, patients’ initial concerns that are discussed with clinicians could be formulated into a list for patients to reflect back 
on before they attend follow‐up review appointments. This would allow patients to consider what had initially concerned them, follow‐up on 
any issues further and remove any old issues that were satisfactorily addressed. It would also enable patients to raise new concerns, or discuss 
changes to their life circumstances, that may have arisen over the review period.
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Taylor et al14 who found that discussion of AS almost immediately 
after the patient had been diagnosed was important to appropriate 
uptake of AS, reducing inappropriate and ill‐informed choices for ac‐
tive treatment.
Patients used information‐seeking strategies to alleviate their 
anxiety. Although they wanted certainty, participants did not explic‐
itly ask clinicians which option they should take. Instead, they sought 
assurance from clinicians by asking if the option they had chosen 
matched what the clinician would have chosen for themselves, had 
they been in the same situation. This finding adds depth to the views 
of Hoffman et al35 where variation between physicians’ recommen‐
dations for low‐risk PCa was identified. In their study, just under half 
of Urologists and oncologists did not make specific treatment rec‐
ommendations, and Urologists were more likely to make recommen‐
dations in line with patients’ preferences.
Compliance with long‐term monitoring of PCa, where patients fail 
to return for clinical review after initial consultation and agreement 
of a treatment path, is an ongoing concern to urology clinicians.8,31 
Embedded within clinics’ patient review processes, engagement with 
an AS protocol may be sustained if patients consider their early inter‐
actions with the Urology clinic have addressed their needs and that 
their prostate health will be expertly, and proactively, monitored.
To optimize engagement with the clinic service, the information 
gaps36 and psychosocial needs7 indicated by patients in this study 
could be addressed by the introduction of a structured process to 
gather, utilize and disseminate information within routine clinical 
care, and incorporate patients’ recommendations for more effec‐
tive risk communication with their clinicians. As described above, 
clinicians in this study communicated with their patients within the 
clinic appointment in a way that supported shared decision making. 
To build on this strength, we propose the use of an information ex‐
change process to ensure patients and clinicians receive appropriate, 
well‐timed information in an accessible format to assist their decision 
making. As the specialist Prostate Cancer Nurse already provides pa‐
tients and families with health literature and links to PCa support 
services, this process may be best coordinated through the specialist 
Prostate Cancer Nurse service. To our knowledge, this study is the 
first to derive a structured process of information exchange for treat‐
ment of low‐risk PCa from the combined perspectives of patients 
and clinicians. Table 6 offers brief recommendations based on our 
findings. The effectiveness of such an approach requires evaluation.
4.1 | Limitations
Although patient recruitment was limited to patients considered 
suitable for AS by the two participating Urologists, there was vari‐
ation within the patient group. Not all patients had PCa, and not all 
were using AS. Nevertheless, this variation resulted in more complex 
data, deepening our understanding of how patients appraise risk and 
make decisions based on this appraisal. Time frame sampling was a 
strength in accessing a more naturalistic sample, but because of the 
imposed time constraint, limited the sample size.
This study has generated a hypothesis about effectiveness 
rather than proving effectiveness with a small participant cohort. 
Evaluation of the effectiveness of the approach we are suggest‐
ing has the potential to optimize engagement between health‐care 
professionals and patients and amongst health‐care professionals, 
leading to greater shared care and shared decision making within 
the consultation. While this is currently missing, evaluation of effec‐
tiveness would form an invaluable element of further research, using 
both quantitative, demonstrable measures and qualitative, in‐depth 
assessment to clarify the use and value of a new information ex‐
change system for all concerned.
The study took place in a single private health clinic using a small 
patient and clinician cohort. Patients were from Anglo‐Australian 
backgrounds and well‐educated, which may reflect those patients 
interested in research participation. Only one Urologist partici‐
pated in an interview, preventing comparison between interview 
the Urologists involved. Consultations with the Prostate Cancer 
Nurse also were unable to be observed. As such, the findings are 
unable to be generalized to larger or publicly funded urology ser‐
vices. Nevertheless, we have gained rich and extensive insight into 
how men from diverse age groups and life stages appraise risk and 
identify their priorities and information needs, which we think have 
scope for other urology studies.
Female researchers interviewed male patients and clinicians in 
a specifically male health area. It is unknown whether this had any 
impact on recruitment to the study or the type of information partic‐
ipants were willing to divulge.
5  | CONCLUSION
Men living with localized PCa, using an AS protocol to manage their 
condition, appraise risk in interrelated ways. Understanding of the 
risks they face, and awareness of their personal priorities, formed 
the basis of discussions with their clinicians. Our findings that pa‐
tient's appraisal of risk was influenced by their priorities and infor‐
mation sources indicate that effective risk communication in PCa 
could be enhanced by well‐timed provision of information aligned 
to patients’ priorities, to reduce anxiety and uncertainty. Patients 
and clinicians could benefit from a structured process to identify pa‐
tients’ priorities prior to consultation, where the complexities of risk 
are discussed in ways that are meaningful to them. Additionally, ac‐
cess to a specialist Prostate Cancer Nurse contributed to the quality 
of, and satisfaction with, the service offered by the clinic, providing a 
valuable model of service delivery incorporating patient‐centric risk 
assessment procedures and care. By explicitly addressing patients’ 
needs, patient engagement with the clinic service may be enhanced 
over time.
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